Summary. An assay to determine the anti-oestrogenic potency of progestagens in women is described. The progressive increase in endometrial glandular suppression with increasing doses of progestagens is the basis of the assay. Norethindrone (oestrogen free) is three times as potent as chlormadinone acetate with a 95% confidence limit of 2\m=.\3to 4\m=.\0.This is in contrast to the greater secretory potency of chlormadinone acetate. It is suggested that the anti-oestrogenic action of progestagens is of some importance in the selection of compounds for contraceptives of the combined progestagen\p=m-\oestrogen, and of great importance for those of the continuous low dose progestagen types. This property may also be desirable in the treatment of both endometrial hyperplasia and adenocarcinoma.
INTRODUCTION
The progestagen component of the progestagen-oestrogen oral contraceptive mixtures produces secretory exhaustion of the endometrial glands and exerts a restraint upon their development and maturation (Maqueo-Topete, PerezVega, Goldzieher, Martinez-Manautou & Rudel, 1963) . Thus, at the conclusion of a 20-day regimen with one of these agents, the endometrial histology may vary from complete absence of glandular secretion and tortuosity to one of suppressed activity, with some cellular or intraluminal secretion and minimal to moderate tortuosity. In no case is there a fully developed secretory endometrium characteristic of the late luteal phase of the menstrual cycle. This inhibitory effect has been thought to be due to the anti-oestrogenic property of the progestagen in that complete glandular suppression has been prevented by beginning the progestagen-oestrogen therapy on Day 10 of the menstrual cycle rather than on Day 5, allowing for five additional days of endogenous oestrogen stimulation of the endometrium (Rudel, Maqueo-Topete & MartinezManautou, 1964 (Rudel & Kincl 1966 (Kincl, 1961; Kincl & Folch-Pi, 1962) . Norethindrone, on the other hand, is about ten times more potent than chlormadinone acetate as an anti-oestrogen in the mouse antiuterotrophic assay (Dorfman, Kincl & Ringold, 1961 ; Dorfman & Kincl, 1963) .
MATERIALS AND METHODS
Women of known fertility and with regular menstrual cycles were treated for one cycle with one of the following: chlormadinone acetate, 0-2, 0-3, 0-4, 0-5, 1-0 and 4-0 mg; norethindrone (oestrogen free), 0-05, 0-1, 0-2, 0-25, 0-5 and 1 -0 mg. Therapy was given in a single daily oral dose for 20 days, starting on Day 5 of the menstrual cycle. A biopsy was taken from each patient between (Boschann, 1958) 
